Nutra Pharma Corp (NPHC) Stock Price & Analysis

Nutra Pharma Corp (NPHC) rose 0.00% to USD 0 as of July 25, 2026 at 05:01 UTC, according to Nexqual real-time market data.

NPHC last closed at USD 0; the session ranged USD 0–0 on volume of 688 shares. Market capitalization is $2.15M, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, July 25, 2026 at 05:01 UTC.

Key Statistics (as of July 25, 2026 at 05:01 UTC)

Technical Analysis (NPHC)

Nexqual's technical model rates NPHC "STRONG BUY" based on 4 bullish and 0 bearish signals across 124 daily candles, as of July 25, 2026 at 05:01 UTC.

Analyst Ratings (NPHC)

Wall Street analysts rate NPHC "None", per Nexqual as of July 25, 2026 at 05:01 UTC.

Earnings (NPHC)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 05:01 UTC.

Financials & Fundamentals (NPHC)

Source: Nexqual, July 25, 2026 at 05:01 UTC.

Financial Health Score (NPHC)

Nexqual rates Nutra Pharma Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:01 UTC.

Ownership (NPHC)

Source: Nexqual, July 25, 2026 at 05:01 UTC.

Leadership (NPHC)

Nutra Pharma Corp is led by Michael D. Flax D.D.S., M.S., P.A. (age 69), President, CEO, CFO & Chairman, per Nexqual as of July 25, 2026 at 05:01 UTC.

From Nutra Pharma Corp's Latest SEC 10-K Filing (filed 2026-05-20)

Key Strengths & Strategy (as disclosed to the SEC)

• Equine Pain-Away is being marketed through several retailers and online at www.EquinePainAway.com and on Amazon.   Regulation   The active pharmaceutical ingredient (API) in our over the counter products, Asian cobra venom, has an approved United States monograph under the Homeopathic Pharmacopoeia of the United States (HPUS), which allowed us to register them with the United States Food and Drug Administration (FDA) as homeopathic drugs.
• The FDA does not offer this program.   Clinical Trial Applications   We have developed Common Technical Documents (CTD) for both RPI-78M and RPI-MN that are used to support any clinical trial application.
• Delays imposed by governmental marketing approval processes may materially reduce the period during which a company will have the exclusive right to exploit patented products or technologies.
• In addition to obtaining FDA approval for each biological or chemical product, an Establishment License Application ("ELA") must be filed and the FDA must inspect and license the manufacturing facilities for each product.

Partnerships

• It is our plan to eventually re-launch Cobroxin with an eventual return to retail stores.   In December of 2013, we announced an agreement with MyNyloxin.com for the exclusive rights to market and distribute Nyloxin in the Network Marketing channel.
• This included a variety of dietary supplements, which were transitioned to Avini Health beginning in the fourth quarter of 2025, while the Company retained ownership of its cobra venom technology under individual brands .   Marketing and Distribution   In August 2009, we completed an agreement with XenaCare granting them the exclusive license to market and distribute Cobroxin within the United States.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:01 UTC. This page is informational and not investment advice.